Abstract::
Genetic, experimental and clinical studies have consistently confirmed that inhibition of proprotein
convertase subtilisin/kexin type 9 (PCSK9) can result in significant LDL-C lowering and two fully human
PCSK9 mononclonal antibodies have received regulatory approval for use in high-risk patients. Co-
administration of PCSK9 with statins has resulted in extremely low LDL-C levels with excellent short-term
safety profiles. While results from Phase III clinical trials provided exciting evidence about the role … Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.